


Remarks

This application was filed as a continuation of USSN 09/504,735. In fact, it is a divisional, pursuant to the restriction requirement levied in Paper 8 of parental USSN 08/338,368. The restriction requirement the original case identified 3 independent inventions: The isolated protein NP (Group I), nucleic acid encoding same and related technology (Group II) and methods-of-therapy using the NP (Group III). The first two Groups have been prosecuted to allowance in the parent cases. The present application therefore is directed to the method-of-therapy claims, claims 33-38. The New Application Transmittal form mailed with this application cancelled claims 2-25 and 39, but not the other previously prosecuted subject matter. Accordingly, an appropriate amendment has been made herein to place the case in better condition for examination.

A Form-1449 is submitted herewith to cite the prior art considered in the parental applications. Those applications are believed to contain copies of the references but, if not, applicants will supply them upon request.

Respectfully Submitted,



Max D. Hensley
Reg. No. 27,043
Phone: (650) 522-5546
Fax: (650) 522-5575
email: ip@gilead.com
Date: March 17, 2005

Attachments:

Transmittal of Information Disclosure Statement
Amendment Transmittal
Information Disclosure Statement - 1449 Form